The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, inducing deep molecular responses, largely improving patient survival and rendering treatment-free remission possible. However, three of the five BCR-ABL TKIs, dasatinib, nilotinib, and ponatinib, inc...

Full description

Bibliographic Details
Main Authors: Hélène Haguet, Céline Bouvy, Anne-Sophie Delvigne, Elise Modaffari, Adeline Wannez, Pierre Sonveaux, Jean-Michel Dogné, Jonathan Douxfils
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Pharmacology
Subjects:
BCR-ABL tyrosine kinase inhibitor
chronic myeloid leukemia
endothelial cells
atherosclerosis
cardiovascular
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01007/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01007/full

Similar Items